MDxHealth SA (Euronext: MDXH.BR) today announced that it received the following notification of significant shareholdings, in conformity with Article 15 of the Belgian Act of May 2, 2007 on the publication of significant shareholdings in issuers which shares are admitted to trading on a regulated market.
Shareholdings after actively crossing the transparency threshold:
Capfi Delen Asset Management informed MDxHealth on May 11, 2017 that, as of May 8, 2017, its participation in MDxHealth increased above the threshold of 3% of the outstanding shares. Capfi Delen Asset Management now owns 1,522,000 shares, i.e. 3.05 %, of the outstanding shares of MDxHealth. Capfi Delen Asset Management is a Belgian Management Company of UCITS. For further information, reference is made to the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth.